{"denoms":[{"counts":[{"groupId":"BG000","value":"45"}],"units":"Participants"}],"groups":[{"description":"Thalidomide 200 mg PO once a day initial dose (each 28-day period will be considered one cycle). Dose increased by 200 mg every 2 weeks to maximum dose of 1000 mg/day until disease progression or adverse effects prohibit further therapy.","id":"BG000","title":"Thalidomide"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.9","value":"65.6"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"30-39 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"40-49 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"50-59 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"23"}]}],"title":"60-69 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}],"title":"70-79 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"80-89 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"45"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"45"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"22"}]}],"title":"Carcinosarcoma-homologous"},{"categories":[{"measurements":[{"groupId":"BG000","value":"16"}]}],"title":"Carcinosarcoma-heterologous"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"Carcinosarcoma, MMT"}],"paramType":"NUMBER","title":"Histologic type","unitOfMeasure":"participants"}],"populationDescription":"Eligible and treated patients."}